#1 Clinical Trials Search in Europe

Efzofitimod

Efzofitimod is an experimental drug being studied in clinical trials for various lung conditions, including systemic sclerosis-related interstitial lung disease (SSc-ILD), pulmonary sarcoidosis, and severe pneumonia related to COVID-19. These trials aim to evaluate the safety, efficacy, and tolerability of efzofitimod in patients with these challenging respiratory conditions.

Table of Contents

What is Efzofitimod?

Efzofitimod is a new drug being studied for its potential to treat various lung diseases. It is also known by other names such as ATYR1923 and KRP-R120[1]. This medication is currently undergoing clinical trials to evaluate its effectiveness and safety in treating several respiratory conditions.

What Conditions Does Efzofitimod Treat?

Efzofitimod is being investigated for the treatment of several lung-related conditions:

  • Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD): This is a condition where the lungs become scarred, making it difficult to breathe[2].
  • Pulmonary Sarcoidosis: A disease characterized by the growth of tiny collections of inflammatory cells in different parts of the body, particularly the lungs[1].
  • Severe Pneumonia related to COVID-19: In the early stages of the pandemic, efzofitimod was also studied for its potential to help patients with severe lung inflammation caused by COVID-19[3].

How is Efzofitimod Administered?

Efzofitimod is given as an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein. The dosage and frequency of administration may vary depending on the condition being treated:

  • For SSc-ILD, it’s being tested at doses of 270 mg and 450 mg, given every 4 weeks[2].
  • For pulmonary sarcoidosis, doses of 3 mg/kg and 5 mg/kg are being studied, also given every 4 weeks[1].
  • In the COVID-19 study, single doses of 1 mg/kg and 3 mg/kg were tested[3].

Each infusion typically takes about 60 minutes to complete.

Current Clinical Trials

Efzofitimod is currently being evaluated in several clinical trials:

  1. A Phase 2 study for SSc-ILD, which aims to assess the drug’s effectiveness in improving lung function and reducing skin thickening[2].
  2. A Phase 3 study for pulmonary sarcoidosis, which is testing whether efzofitimod can help reduce the need for oral corticosteroids (a type of anti-inflammatory medication) while improving lung function[1].
  3. A completed study on severe COVID-19 pneumonia, which evaluated the safety and potential benefits of efzofitimod in this acute condition[3].

Potential Benefits of Efzofitimod

While research is still ongoing, efzofitimod shows promise in several areas:

  • Improved Lung Function: The drug is being studied for its ability to slow down or stop the decline in forced vital capacity (FVC), which is a measure of how much air a person can exhale[2].
  • Reduced Inflammation: Efzofitimod may help decrease inflammation in the lungs, which could lead to symptom improvement in conditions like sarcoidosis[1].
  • Steroid-Sparing Effect: In sarcoidosis, one goal is to see if efzofitimod can help patients reduce their reliance on corticosteroids, which can have significant side effects when used long-term[1].
  • Quality of Life Improvement: Researchers are also looking at whether the drug can improve patients’ overall quality of life, as measured by specialized questionnaires[1].

Side Effects and Safety

As with any new medication, understanding the safety profile of efzofitimod is a crucial part of the ongoing clinical trials. Researchers are carefully monitoring for any adverse events (side effects) that may occur during treatment[3].

It’s important to note that because efzofitimod is still in the testing phase, not all potential side effects may be known. Patients participating in clinical trials are closely monitored for any unexpected reactions or safety concerns.

If you’re interested in learning more about efzofitimod or are considering participating in a clinical trial, it’s essential to discuss this with your healthcare provider. They can provide more information about the potential risks and benefits based on your individual health situation.

Aspect Details
Drug Name Efzofitimod (also known as ATYR1923, KRP-R120)
Administration Method Intravenous (IV) infusion
Conditions Studied Systemic Sclerosis-related Interstitial Lung Disease (SSc-ILD), Pulmonary Sarcoidosis, Severe COVID-19 Pneumonia
Key Outcome Measures Forced Vital Capacity (FVC), Oral Corticosteroid dose reduction, Time to hospital discharge, WHO Ordinal Scale scores
Study Designs Randomized, Double-blind, Placebo-controlled
Treatment Duration Varies by study: 24 weeks for SSc-ILD, 48 weeks for Pulmonary Sarcoidosis, Single dose for COVID-19
Dosages Tested Ranging from 1 mg/kg to 5 mg/kg, with some studies using fixed doses of 270 mg and 450 mg

FAQ

  • What is efzofitimod? Efzofitimod is an experimental drug being tested in clinical trials for various lung conditions. It is administered through intravenous (IV) infusion and is being studied for its potential to treat interstitial lung disease, pulmonary sarcoidosis, and severe pneumonia related to COVID-19.
  • What conditions are being studied with efzofitimod? Clinical trials are investigating efzofitimod for systemic sclerosis-related interstitial lung disease (SSc-ILD), pulmonary sarcoidosis, and severe pneumonia related to COVID-19. These are all serious lung conditions that can significantly impact a person's breathing and quality of life.
  • How is efzofitimod administered in these trials? In the clinical trials, efzofitimod is given as an intravenous (IV) infusion. The frequency and dosage vary depending on the specific trial and condition being studied. For example, in some trials, it's administered every 4 weeks, while in others, it may be given as a single dose.
  • What are the main goals of these clinical trials? The main goals of these clinical trials are to evaluate the safety, efficacy, and tolerability of efzofitimod in patients with various lung conditions. Researchers are looking at how the drug affects lung function, reduces the need for other medications like corticosteroids, and improves overall quality of life for patients.
  • Are there any side effects associated with efzofitimod? As with any experimental drug, the full range of potential side effects is still being studied. The clinical trials are designed to monitor for any adverse events or serious side effects that may occur during treatment. This information will help determine the safety profile of efzofitimod.

Ongoing Clinical Trials on Efzofitimod

  • Study on Efzofitimod for Treating Pulmonary Sarcoidosis in Patients

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Spain

Glossary

  • Interstitial Lung Disease (ILD): A group of disorders that cause inflammation and scarring in the lungs, making it difficult to breathe and get enough oxygen into the bloodstream.
  • Systemic Sclerosis (SSc): A rare autoimmune disease that causes hardening and tightening of the skin and can affect internal organs, including the lungs.
  • Pulmonary Sarcoidosis: A condition where small clumps of inflammatory cells grow in the lungs, causing breathing difficulties and other symptoms.
  • Forced Vital Capacity (FVC): The total amount of air exhaled during a forced breath, which is an important measure of lung function.
  • Oral Corticosteroid (OCS): A type of medication taken by mouth to reduce inflammation in various parts of the body, including the lungs.
  • Intravenous (IV) Infusion: A method of delivering medication directly into a vein using a needle or catheter.
  • Placebo: A substance with no active medical benefits, used in clinical trials to compare the effects of a new drug against a non-active treatment.
  • Double-blind Study: A type of clinical trial where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • Proof-of-Concept (PoC) Study: An early-stage trial designed to test whether a treatment might be effective before moving on to larger, more comprehensive studies.
  • World Health Organization (WHO) Ordinal Scale: A scoring system used to assess the clinical status of patients, particularly in COVID-19 studies, ranging from 0 (no symptoms) to 8 (death).

References

  1. https://clinicaltrials.eu/trial/study-on-efzofitimod-for-treating-pulmonary-sarcoidosis-in-patients/
  2. https://clinicaltrials.gov/study/NCT05892614
  3. https://clinicaltrials.gov/study/NCT04412668